Emergent BioSolutions | EBS - Current Liabilities


Emergent BioSolutions reported $651.3M in Current Liabilities for its fiscal quarter ending in December of 2023.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Akebia Therapeutics USD 162.94M 29.56M Dec/2025
ALKERMES USD 543.44M 69.08M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 194.46M 12.23M Dec/2025
ANI Pharmaceuticals USD 278.11M 7.56M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Exelixis USD 405.64M 31.86M Dec/2025
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Ironwood Pharmaceuticals USD 242.5M 9.98M Sep/2025
Lexicon Pharmaceuticals USD 20.87M 853K Dec/2025
Lonza CHF 3.57B 421M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.99B 306M Dec/2025
Myriad Genetics USD 133.8M 14.2M Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Pacira USD 120.59M 13.51M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
United Therapeutics USD 560.6M 14.3M Dec/2025
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Xoma USD 28.3M 6.81M Sep/2025